Beyond the target pathogen: Ecological effects of the hospital formulary

Current Opinion in Infectious Diseases

Volumn 24, Issue SUPPL. 1, 2011, Pages

  Goldstein, Ellie J C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

carbapenem; Clostridium difficile infection; collateral damage; susceptibility breakpoint

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEFTRIAXONE; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTESTINE FLORA; MULTICENTER STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FORMULARIES, HOSPITAL; HUMANS; UNITED STATES;

EID: 78751484676     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000393485.17894.4c     Document Type: Article

References (81)

1. Paterson DL. 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 (Suppl 4):S341-S345.
2. Weber DJ. Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. Int J Infect Dis 2006; 10:S17-S24.
3. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am 2009; 23:727-743.
4. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006; 73:187-197.
5. Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol 2009; 27:289-300.
6. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-931.
7. Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J 2008; 27:1111-1113.
8. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13: 1417-1419.
9. Centers for Disease Control and Prevention. Data & statistics about Clostridium difficile infections. http://www.cdc.gov/ncidod/dhqp/id-Cdiff-data. html. [Accessed 26 May 2010].
10. Kyne L, Hamel MB, Polavaram R, Kelly CP. Healthcare costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-353.
11. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142:624-631; discussion 631.
12. Marra AR, Edmond MB, Wenzel RP, Bearman GM. Hospital-acquired Clos-tridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis 2007; 7:42.
13. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001; 7:405-410.
14. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1-15.
15. Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-1549.
16. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-397.
17. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008; 24:4-10.
18. Federle MJ, Bassler BL. Interspecies communication in bacteria. J Clin Invest 2003; 112:1291-1299.
19. Williams P, Winzer K, Chan WC, Camara M. Look who's talking: communication and quorum sensing in the bacterial world. Philos Trans R Soc Lond B Biol Sci 2007; 362:1119-1134.
20. Shank EA, Kolter R. New developments in microbial interspecies signaling. Curr Opin Microbiol 2009; 12:205-214.
21. Edmiston CE, Walker AP. Microbiology of intraabdominal infections. Infect Dis Clin Pract 1996; 5:S15-S19.
22. Finegold SM. Anaerobic bacteria in human disease. New York: Academic Press Inc; 1977.
23. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449.
24. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-645. (Pubitemid 38333858)
25. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441.
26. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1):S43-S49.
27. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
28. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Infect Control Hosp Epidemiol 2009; 30:156-162.
29. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastro-enterol 2010; 105:2327-2339.
30. Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 2009; 33 (Suppl 1):S51-S56.
31. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105:1636-1641.
32. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with nontoxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009; 33 (Suppl 1):S46-S50.
33. Trejo FM, Perez PF, De Antoni GL. Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro. Antonie Van Leeuwenhoek 2010; 98:19-29.
34. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clinda-mycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998; 128:989-995.
35. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005:CD003543.
36. Fowler S,WebberA,Cooper BS,et al, Successfuluse of feedbackto improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother, 2007, 59, 990-995.
37. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003; 54:104-108.
38. Ludlam H, Brown N, Sule O, et al. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing 1999; 28:578-580.
39. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 2004; 97:423-429.
40. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45 (Suppl 2):S112-S121.
41. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15:274-280.
42. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177.
43. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis 2009; 22:352-358.
44. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6:751-763.
45. Kumarasamy KK, Toleman MA, Walsh TR,et al. Emergenceof a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
46. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America; 2004.
47. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-164.
48. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006; 119:S3-S10; discussion S62-S70.
49. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. Br J Pharmacol 2008; 153 (Suppl 1):S347-S357.
50. Mazel D. Integrons: agents of bacterial evolution. Nat Rev Microbiol 2006; 4:608-620.
51. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CSLI document M100-S20. Wayne, PA: CLSI; 2010.
52. EUCAST definitions of clinical breakpoints and epidemiological cut-off values., http://www.srga.org/Eucastwt/eucastedfinitions.htm. [Accessed 18 June 2010].
53. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20:391-408; table of contents.
54. Rice LB. Federal funding for the study of antimicrobial resistance in noso-comial pathogens: no ESKAPE. J Infect Dis 2008; 197:1079-1081.
55. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12:476-481.
56. Bronze MS, Dale JB. The reemergence of serious group A streptococcal infections and acute rheumatic fever. Am J Med Sci 1996; 311:41-54.
57. Seppala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326:292-297.
58. Seppala H, Klaukka T, Lehtonen R, et al. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21:1378-1385.
59. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441-446.
60. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-1237.
61. Pultz MJ, Donskey CJ. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrob Agents Chemother 2007; 51:3044-3045.
62. Dela Pena AS,AspergerW,KockerlingF,etal.Efficacyand safetyofertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 2006; 10:567-574.
63. Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24:443-449.
64. Chen PL, Yan JJ, Wu CJ, et al. Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2010; 68:312-314.
65. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobac-ter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63:659-667.
66. Garcia-Fernandez A, Miriagou V, Papagiannitsis CC, et al. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumo-niae clone carries a novel OmpK36 porin variant. Antimicrob Agents Che-mother 2010; 54:4178-4184.
67. Lartigue MF, Poirel L, Poyart C, et al. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13:315-317.
68. Yan JJ, Wu JJ, Lee CC, et al. Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007. Eur J Clin Microbiol Infect Dis 2010; 29:1417-1425.
69. DiNubile MJ, Friedland IR, Chan CY, et al. Bowel colonization with vanco-mycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. Diagn Microbiol Infect Dis 2007; 58:491-494.
70. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal orophar-yngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50:3375-3380. (Pubitemid 44527513)
71. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-pro- ducing organisms. J Hosp Infect 2009; 73:345-354.
72. Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008; 6:671-683.
73. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65:2151-2178.
74. Crank CW, Hota B, Segreti J, Stroger JHJ. Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility to imipenem [abstract no.285]. 44th Annual Meeting of IDSA; 12-15 October 2006; Toronto.
75. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31:485-490.
76. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect 2008; 57:123-127.
77. Goldstein EJ, Citron DM, Peraino V, et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:5122-5126.
78. Lima AL, Oliveira PR, Paula AP, et al. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009; 30:487-490.
79. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-1986.
80. Bosso JA, Mauldin PD, Salgado CD. The association between antibiotic use and resistance: the role of secondary antibiotics. Eur J Clin Microbiol Infect Dis 2010 [Epub ahead of print].
81. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003; 23:916-924.